Search

Your search keyword '"Filleron, T."' showing total 633 results

Search Constraints

Start Over You searched for: Author "Filleron, T." Remove constraint Author: "Filleron, T."
633 results on '"Filleron, T."'

Search Results

6. Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial

13. 217P Incidence and outcome of brain and/or leptomeningeal metastatic disease in HER2-low breast cancer in the French ESME cohort

16. Pseudoprogression versus true progression in patients with glioblastoma: A multiapproach analysis

18. Prospective Assessment of First-Year Quality of Life After Pelvic Exenteration for Gynecologic Malignancy: A French Multicentric Study

21. Comment effectuer des comparaisons indirectes ajustées par appariement (MAIC) avec imputations multiples des données manquantes et dans un contexte de faibles échantillons ? Une méthodologie illustrée dans le cancer du poumon à partir d'essais cliniques agrégés et de la cohorte nationale ESME-AMLC

23. 260P Antitumor activity of trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (mBC) and brain metastases (BMs) from DAISY trial

40. Évaluation en vie réelle du pembrolizumab en monothérapie dans le traitement du CBNPC métastatique PD-L1-positif (TPS ≥ 50 %) en France

41. Évaluation en vie réelle du pembrolizumab en monothérapie dans le CBNPC avancé PD-L1 positif (TPS ≥ 1 %) précédemment traité, en France

42. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†

45. 1842P Molecular testing in older patients treated for an advanced or metastatic non-squamous non-small cell lung cancer

46. Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†

47. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†

48. OC-0333 Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial

50. Exploratory analyses of surrogate endpoints in metastatic non-small cell lung cancer

Catalog

Books, media, physical & digital resources